Based on its analysis of the global intelligent imaging analysis systems market, Frost & Sullivan recognized RapidAI with the 2020 Global Growth, Innovation and Leadership Frost Radar Award.
RapidAI™ empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically proven, data-driven technology. With our validated, trusted platform developed by medical experts, clinicians worldwide are improving patient care and outcomes every day.
RapidAI offers an end-to-end portfolio of advanced stroke imaging and stroke assessment products for hospitals of all sizes. The Rapid platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans, helping hospitals to speed up time-critical triage or transfer decisions and facilitate better patient outcomes.
Rapid Aneurysm, a cloud-based computational platform, provides comprehensive cerebral aneurysm management—automating the entire workflow from initial assessment to growth monitoring and treatment planning.
A fully automated system that uses the latest in artificial intelligence technology to quickly triage non-contrast CT (NCCT) cases to notify physicians of possible intracranial hemorrhage (ICH) within three minutes of case receipt.
Rapid ASPECTS, based on the Alberta Stroke Program Early CT Score (ASPECTS) system, uses a validated machine-learning algorithm to automatically identify the ASPECTS regions of the brain and generate an ASPECT score
Rapid CTA and Rapid LVO help physicians quickly identify suspected large vessel occlusions (LVOs) by automatically processing CT scans and delivering clear, easy-to-interpret CT angiography images.
Rapid CTP enables physicians to assess salvageable brain tissue through the delivery of quantified and color-coded CT perfusions maps that identify brain regions with reduced cerebral blood flow, volume, density, and transit time.
Rapid MRI helps physicians assess salvageable brain tissue through the delivery of quantified and color-coded MR diffusion and perfusion maps that identify brain regions with reduced apparent diffusion coefficient (ADC) and transit time.
A portfolio of analytic reports presenting data about Rapid scan, treatment, and outcomes data designed to help sites and systems make more informed business decisions and save money.
Get notifications for new cases and access Rapid results using Google Chrome or Microsoft Edge on any desktop or laptop — saving you and your patients precious time.
The Rapid Mobile App gives physicians the ability to receive anywhere, anytime notifications of new cases, preview Rapid results and source files, and enable workflow communications among stroke team members via their mobile devices.
Initially validated by an NIH-sponsored DEFUSE 2 study published in 2012, and further studied by numerous worldwide trials, RapidAI continues to show evidence of success, ultimately helping healthcare professionals save lives.
“...RAPID is unparalleled in ease of implementation and use. RAPID elevates perfusion imaging in the management of acute ischemic stroke.”
“I’ve always pushed for faster reviewing of images. Now, through RapidAI, we have it"
“...Rapid...shifts our 'speed to decision' to less than two minutes and is accessible 24/7/365.”